30 Oct 2026

Italy’s Government has proposed two changes to pharmaceutical expenditure controls in Article 71 of its 2027–2029 Budget Bill, sent to Parliament on 30 October. The measures would increase the statutory ceiling for medicines bought directly by public healthcare providers and offer conditional relief from expenditure payback.

From 2028, the direct-purchase ceiling would rise by 0.2 percentage points to 9% of national health-service funding, including the provision for medical gases. The increase represents approximately €292 million a year in recognised spending capacity. It would change the threshold against which excess expenditure is calculated, not the prices paid for individual medicines.

The second measure would reduce manufacturers’ payback liabilities where they make qualifying additional investments in Italy. A national fund of up to €160 million a year from 2027 would compensate regions for the resulting reduction in receipts. The investments could cover research, clinical trials, manufacturing and other specified strategic activities. The draft also extends the mechanism to qualifying investment made in 2026.

Current rules require pharmaceutical companies to contribute to expenditure exceeding the direct-purchase ceiling. The September LiSAH report documented continuing pressure on that ceiling, while the October AIFA determination converted the 2025 excess into company liabilities.

Both proposals remain subject to parliamentary approval and detailed implementing provisions. They would ease expenditure recovery selectively and link part of that relief to domestic investment, while retaining the underlying payback system.

Source: President of the Italian Republic
Link: D.D.L. 30/10/2026 – Bilancio di previsione dello Stato per l’anno finanziario 2027 e bilancio pluriennale per il triennio 2027–2029 (Draft law of 30 October 2026 – State Budget for 2027 and multiannual Budget 2027–2029)
Date: 30 October 2026

Source: Il Farmacista Online
Link: Manovra. Ecco il testo con tutte le misure per la sanità e la farmaceutica (Budget: full text and measures for healthcare and pharmaceuticals)
Date: 30 October 2026